{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cell+Therapy&page=11",
    "query": {
      "intervention": "Cell Therapy",
      "page": 11
    },
    "page_size": 10
  },
  "pagination": {
    "page": 11,
    "page_size": 10,
    "total_count": 12462,
    "total_pages": 1247,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cell+Therapy&page=12&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cell+Therapy&page=10&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-22T04:35:06.277Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03340558",
      "title": "Atezolizumab Monotherapy vs Atezolizumab Plus Cobimetinib in Liver Metastases From Colorectal Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cobimetinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Niharika Mettu",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2018-05",
      "completion_date": "2025-02",
      "has_results": false,
      "last_update_posted_date": "2018-10-09",
      "last_synced_at": "2026-10-22T04:35:06.277Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03340558"
    },
    {
      "nct_id": "NCT01728207",
      "title": "Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-hodgkin's Lymphoma",
        "Follicular Lymphoma",
        "Mantle Cell Lymphoma",
        "Marginal Zone Lymphoma",
        "Chronic Lymphocytic Leukemia",
        "Small Lymphocytic Lymphoma"
      ],
      "interventions": [
        {
          "name": "IMMU-114",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2013-03",
      "completion_date": "2017-03",
      "has_results": false,
      "last_update_posted_date": "2021-08-19",
      "last_synced_at": "2026-10-22T04:35:06.277Z",
      "location_count": 5,
      "location_summary": "Newark, Delaware • Savannah, Georgia • Goshen, Indiana + 2 more",
      "locations": [
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Savannah",
          "state": "Georgia"
        },
        {
          "city": "Goshen",
          "state": "Indiana"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01728207"
    },
    {
      "nct_id": "NCT03899792",
      "title": "A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Medullary Thyroid Cancer",
        "Infantile Myofibromatosis",
        "Infantile Fibrosarcoma",
        "Papillary Thyroid Cancer",
        "Soft Tissue Sarcoma"
      ],
      "interventions": [
        {
          "name": "Selpercatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "6 Months to 21 Years"
      },
      "enrollment_count": 36,
      "start_date": "2019-06-13",
      "completion_date": "2029-05",
      "has_results": true,
      "last_update_posted_date": "2026-01-06",
      "last_synced_at": "2026-10-22T04:35:06.277Z",
      "location_count": 12,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Orlando, Florida + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03899792"
    },
    {
      "nct_id": "NCT00482092",
      "title": "Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Crohn's Disease"
      ],
      "interventions": [
        {
          "name": "Prochymal®",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mesoblast, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 330,
      "start_date": "2007-09-17",
      "completion_date": "2014-09-15",
      "has_results": false,
      "last_update_posted_date": "2026-03-11",
      "last_synced_at": "2026-10-22T04:35:06.277Z",
      "location_count": 47,
      "location_summary": "Los Angeles, California • San Francisco, California • Wheat Ridge, Colorado + 38 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Wheat Ridge",
          "state": "Colorado"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00482092"
    },
    {
      "nct_id": "NCT06855771",
      "title": "A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "interventions": [
        {
          "name": "BMS-986504",
          "type": "DRUG"
        },
        {
          "name": "Izalontamab Brengitecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 182,
      "start_date": "2025-09-09",
      "completion_date": "2031-12-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-18",
      "last_synced_at": "2026-10-22T04:35:06.277Z",
      "location_count": 10,
      "location_summary": "Anchorage, Alaska • Boston, Massachusetts • Detroit, Michigan + 6 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06855771"
    },
    {
      "nct_id": "NCT00006244",
      "title": "Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Refractory Multiple Myeloma",
        "Stage I Multiple Myeloma",
        "Stage II Multiple Myeloma",
        "Stage III Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "melphalan",
          "type": "DRUG"
        },
        {
          "name": "recombinant interferon alfa",
          "type": "BIOLOGICAL"
        },
        {
          "name": "aldesleukin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "in vitro-treated peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "69 Years",
        "sex": "ALL",
        "summary": "18 Years to 69 Years"
      },
      "enrollment_count": 36,
      "start_date": "2000-02",
      "completion_date": "2016-04",
      "has_results": true,
      "last_update_posted_date": "2017-07-12",
      "last_synced_at": "2026-10-22T04:35:06.277Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00006244"
    },
    {
      "nct_id": "NCT04197934",
      "title": "WSD0922-FU for Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Anaplastic Astrocytoma, IDH-Wildtype",
        "Glioblastoma, IDH-Wildtype",
        "Metastatic Lung Non-Small Cell Carcinoma",
        "Metastatic Malignant Neoplasm in the Central Nervous System",
        "Stage IV Lung Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection - blood samples",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection - CSF samples",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "EGFR/EGFRvIII Inhibitor WSD0922-FU",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Therapeutic Conventional Surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 56,
      "start_date": "2019-12-20",
      "completion_date": "2031-02-06",
      "has_results": false,
      "last_update_posted_date": "2026-08-10",
      "last_synced_at": "2026-10-22T04:35:06.277Z",
      "location_count": 3,
      "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04197934"
    },
    {
      "nct_id": "NCT01903993",
      "title": "A Randomized Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - \"POPLAR\"",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 287,
      "start_date": "2013-08-06",
      "completion_date": "2018-09-06",
      "has_results": true,
      "last_update_posted_date": "2019-10-02",
      "last_synced_at": "2026-10-22T04:35:06.277Z",
      "location_count": 29,
      "location_summary": "Tucson, Arizona • Hot Springs, Arkansas • Loma Linda, California + 26 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "San Marcos",
          "state": "California"
        },
        {
          "city": "Vallejo",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01903993"
    },
    {
      "nct_id": "NCT00627393",
      "title": "Safety and Effectiveness of Granulocyte Transfusions in Resolving Infection in People With Neutropenia (The RING Study)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neutropenia",
        "Infection"
      ],
      "interventions": [
        {
          "name": "Standard antimicrobial therapy",
          "type": "DRUG"
        },
        {
          "name": "Granulocyte transfusions",
          "type": "BIOLOGICAL"
        },
        {
          "name": "G-CSF/dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Apheresis machine",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "DEVICE"
      ],
      "sponsor": "Carelon Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 114,
      "start_date": "2008-04",
      "completion_date": "2013-05",
      "has_results": true,
      "last_update_posted_date": "2015-04-17",
      "last_synced_at": "2026-10-22T04:35:06.277Z",
      "location_count": 13,
      "location_summary": "Iowa City, Iowa • Baltimore, Maryland • Boston, Massachusetts + 9 more",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00627393"
    },
    {
      "nct_id": "NCT04586452",
      "title": "NIH CCR2 AAA Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Abdominal Aortic Aneurysm (AAA)",
        "No Abdominal Aortic Aneurysm (Non-AAA)"
      ],
      "interventions": [
        {
          "name": "AAA Group (Aim 3A)",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Non-AAA Group",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Ex Vivo Human AAA Specimens (Aim 2A)",
          "type": "OTHER"
        },
        {
          "name": "Relationship between radiotracer and CCR2 (Aim 2B)",
          "type": "OTHER"
        },
        {
          "name": "AAA Group (Aim 3B-Reproducibility)",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST",
        "OTHER"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2021-02-17",
      "completion_date": "2022-04-04",
      "has_results": false,
      "last_update_posted_date": "2025-07-15",
      "last_synced_at": "2026-10-22T04:35:06.277Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04586452"
    }
  ]
}